



**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

**NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units	Test Report Status	<u>Final</u>	Results	<b>Biological Reference Interval</b>	Units
---	--------------------	--------------	---------	--------------------------------------	-------

## MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

BLOOD COUNTS EDTA WHOLE BLOOD			
BLOOD COUNTS,EDTA WHOLE BLOOD	15.0	12.0 17.0	- / - 1
HEMOGLOBIN  METHOD: PHOTOMETRIC MEASUREMENT	15.3	13.0 - 17.0	g/dL
RED BLOOD CELL COUNT	5.28	4.5 - 5.5	mil/μL
METHOD: COULTER PRINCIPLE			
WHITE BLOOD CELL COUNT	7.90	4.0 - 10.0	thou/µL
METHOD: COULTER PRINCIPLE			
PLATELET COUNT	355	150 - 410	thou/µL
METHOD: ELECTRONIC IMPEDENCE & MICROSCOPY			
RBC AND PLATELET INDICES			
HEMATOCRIT	44.9	40.0 - 50.0	%
METHOD: CALCULATED PARAMETER			
MEAN CORPUSCULAR VOL	85.0	83.0 - 101.0	fL
METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM			
MEAN CORPUSCULAR HGB.	28.9	27.0 - 32.0	pg
METHOD: CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED PARAMETER	34.1	31.5 - 34.5	g/dL
MENTZER INDEX	16.1		
RED CELL DISTRIBUTION WIDTH	12.6	11.6 - 14.0	%
METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM			
MEAN PLATELET VOLUME	7.4	6.8 - 10.9	fL
METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM			
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	48	40 - 80	%
METHOD: VCSN TECHNOLOGY/ MICROSCOPY			
ABSOLUTE NEUTROPHIL COUNT	3.79	2.0 - 7.0	thou/µL
METHOD: CALCULATED PARAMETER			
LYMPHOCYTES	38	20 - 40	%
METHOD: VCSN TECHNOLOGY/ MICROSCOPY			
ABSOLUTE LYMPHOCYTE COUNT	3.00	1.0 - 3.0	thou/µL
METHOD: CALCULATED PARAMETER			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.3		
METHOD: CALCULATED			
EOSINOPHILS	5	1.0 - 6.0	%









CLIENT CODE: C000138379 CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT NAME: JINU T JOHN PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
METHOD: VCSN TECHNOLO					
ABSOLUTE EOSINOPHI		0.40		0.02 - 0.50	thou/µL
METHOD : CALCULATED PAR	RAMETER				
MONOCYTES		8		2.0 - 10.0	%
METHOD: VCSN TECHNOLO					
ABSOLUTE MONOCYTE		0.63		0.2 - 1.0	thou/µL
METHOD : CALCULATED PAR	RAMETER				
BASOPHILS		1		0 - 1	%
METHOD: VCSN TECHNOLO	GY/ MICROSCOPY				
ABSOLUTE BASOPHIL	COUNT	0.08		0.02 - 0.10	thou/µL
METHOD : CALCULATED PAR	RAMETER				
MORPHOLOGY					
RBC		PREDOMINANTL'	Y NORMOC	YTIC NORMOCHROMIC	
METHOD : MICROSCOPIC EX	XAMINATION				
WBC		NORMAL MORPH	IOLOGY		
METHOD : MICROSCOPIC EX	XAMINATION				
PLATELETS		ADEQUATE			
METHOD : ELECTRONIC IMP	EDENCE & MICROSCOPY				
ERYTHROCYTE SEDI BLOOD	MENTATION RATE (ES	SR),WHOLE			
E.S.R		2		0 - 14	mm at 1 hr
METHOD : AUTOMATED (PHO	OTOMETRICAL CAPILLARY STOPP	ED FLOW KINETIC ANALYSIS)			
GLUCOSE FASTING,	LUORIDE PLASMA				
FBS (FASTING BLOOD	SUGAR)	102	High	Normal <100 Impaired fasting glucose:100 to 125 Diabetes mellitus: > = 126 (on more than 1 occassion) (ADA guidelines 2021)	
METHOD : SPECTROPHOTOM	METRY HEXOKINASE			,	
GLYCOSYLATED HEM BLOOD	IOGLOBIN(HBA1C), E	DTA WHOLE			
HBA1C		5.3		Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)	%
METHOD : ION- EXCHANGE	HPLC			-	
ESTIMATED AVERAGE	GLUCOSE(EAG)	105.4		< 116.0	mg/dL

GLUCOSE, POST-PRANDIAL, PLASMA

METHOD: CALCULATED PARAMETER



Page 2 Of 13





**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

**NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	al Units
PPBS(POST PRANDIAL	BLOOD SUGAR)	101		Normal <140 Impaired glucose tolerance:140 to 199 Diabetes mellitus: > = 200 (on more than 1 occassion) ADA guideline 2021	mg/dL
METHOD: SPECTROPHOTOM	ETRY HEXOKINASE			NDN galdeline 2021	
LIPID PROFILE, SER	UM				
CHOLESTEROL, TOTAL	IETRY, ENZYMATIC COLORIMETR	195	STEPASE DEPO	Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL
TRIGLYCERIDES	EINT, ENZIMATIC COLOMPIETO	71	SIEIWSE, PERO	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD : SPECTROPHOTOM	ETRY, ENZYMATIC ENDPOINT W	ITH GLYCEROL BLANK		, , ,	
HDL CHOLESTEROL		43		At Risk: < 40 Desirable: > or = 60	mg/dL
CHOLESTEROL LDL	IETRY, HOMOGENEOUS DIRECT	138	High	Optimal: < 100 Near optimal/above optimal: 1 129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL L00-
METHOD : CALCULATED PAR	AMETER			, ,	
NON HDL CHOLESTERO		152	High	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
METHOD : CALCULATED PAR	AMETER				
CHOL/HDL RATIO  METHOD : CALCULATED PAR	AMETER	4.5	High	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
LDL/HDL RATIO		3.0		Desirable/Low Risk: 0.5 - 3.0 Borderline/Moderate Risk: 3.1 6.0 High Risk: > 6.0	-
METHOD : CALCULATED PAR VERY LOW DENSITY LI METHOD : CALCULATED PAR	POPROTEIN	14.0		< or = 30.0	mg/dL

#### LIVER FUNCTION PROFILE, SERUM









**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

**NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference	Interval Units
BILIRUBIN, TOTAL	0.93		Upto 1.2	mg/dL
METHOD: SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO MET				
BILIRUBIN, DIRECT	0.28	High	0.0 - 0.2	mg/dL
METHOD: SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIA				
BILIRUBIN, INDIRECT	0.65		0.1 - 1.0	mg/dL
METHOD: CALCULATED PARAMETER				
TOTAL PROTEIN	7.1		6.0 - 8.0	g/dL
METHOD: SPECTROPHOTOMETRY, COLORIMETRIC-BIURET, RE	•			
ALBUMIN	5.0	High	3.97 - 4.94	g/dL
METHOD: SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG	•			
GLOBULIN	2.1		2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER				
ALBUMIN/GLOBULIN RATIO	2.4	High	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	22		Upto 40	U/L
METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOS	, ,	CC		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	36		Upto 41	U/L
METHOD: SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOS	. ,	CC		
ALKALINE PHOSPHATASE	69		40 - 129	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC				
GAMMA GLUTAMYL TRANSFERASE (GGT)	24		< 60	U/L
METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC	- G-GLUTAMYL-CARBOXY-NIT	ROANILIDE - IF	-CC	
LACTATE DEHYDROGENASE	149		< 232	U/L
METHOD: SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV	-IFCC			
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	8		6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC				
CREATININE, SERUM				
CREATININE	0.99		0.90 - 1.30	mg/dL
METHOD: SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE	KINETIC - RATE BLANKED - I	FCC-IDMS STAN	IDARIZED	
BUN/CREAT RATIO				
BUN/CREAT RATIO	8.00		8 - 15	
METHOD: CALCULATED PARAMETER				
URIC ACID, SERUM				
URIC ACID	7.2	High	3.4 - 7.0	mg/dL
METHOD: SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC		_		
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	7.1		6.0 - 8.0	g/dL
TO THE PROPERTY	/.1		0.0	9/42







**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

**NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
METHOD : CRECTROPHOTON	METRY COLORIMETRIC RILIRET REACEN	T DI ANIZ CEDUM DI ANIZ			
ALBUMIN, SERUM	METRY, COLORIMETRIC -BIURET, REAGEN	I BLAINK, SERUIT BLAINK			
ALBUMIN		5.0	Hiah	3.97 - 4.94	g/dL
	METRY, BROMOCRESOL GREEN(BCG) - DY		9	3.97 4.94	g/uL
GLOBULIN	,				
GLOBULIN		2.1		2.0 - 3.5	g/dL
METHOD : CALCULATED PAI	RAMETER				5,
ELECTROLYTES (NA	/K/CL), SERUM				
SODIUM		138		136 - 145	mmol/L
METHOD : ISE INDIRECT					
POTASSIUM		4.40		3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT					
CHLORIDE		103		98 - 106	mmol/L
METHOD : ISE INDIRECT					
PHYSICAL EXAMINA	ATION, URINE				
COLOR		PALE YELLOW			
APPEARANCE		CLEAR			
SPECIFIC GRAVITY		1.000	Low	1.010 - 1.030	
CHEMICAL EXAMINA	ATION, URINE				
PH		6.0		5.00 - 7.50	
PROTEIN		NOT DETECTED		NOT DETECTED	
GLUCOSE		NOT DETECTED		NOT DETECTED	
KETONES		NOT DETECTED		NOT DETECTED	
BLOOD		NOT DETECTED		NOT DETECTED	
BILIRUBIN		NOT DETECTED		NOT DETECTED	
UROBILINOGEN		NOT DETECTED			
NITRITE		NOT DETECTED		NOT DETECTED	
LEUKOCYTE ESTERASE		NOT DETECTED		NOT DETECTED	
MICROSCOPIC EXAM	MINATION, URINE				
PUS CELL (WBC'S)		1-2		0-5	/HPF
EPITHELIAL CELLS		0-1		0-5	/HPF
ERYTHROCYTES (RBC'	S)	NOT DETECTED		NOT DETECTED	/HPF
CASTS		NOT DETECTED			
CRYSTALS		NOT DETECTED			
BACTERIA		NOT DETECTED		NOT DETECTED	
YEAST		NOT DETECTED		NOT DETECTED	



Page 5 Of 13 Scan to View Report





CLIENT CODE: C000138379
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

NOT DETECTED

PATIENT NAME: JINU T JOHN PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

#### Comments

NOTE: KINDLY EXERT CAUTION DURING INTERPRETATION OF FINDINGS REPORTED IN URINALYSIS WHERE IN THE SAMPLE IS MORE THAN TWO HOURS OID.

#### THYROID PANEL, SERUM

T3	119.0	80.0 - 200.0	ng/dL
METHOD: COMPETITIVE ELECTROCHEMILUMINES	CENCE IMMUNOASSAY		
T4	8.05	5.10 - 14.10	μg/dL
METHOD: COMPETITIVE ELECTROCHEMILUMINES	CENCE IMMUNOASSAY		
TSH 3RD GENERATION	1.730	0.270 - 4.200	μIU/mL
METHOD: SANDWICH ELECTROCHEMILUMINESCE	ENCE IMMUNOASSAY		

STOOL: OVA & PARASITE

COLOUR	BROWN	
CONSISTENCY	SEMI FORMED	
ODOUR	FAECAL	
MUCUS	NOT DETECTED	NOT DETECTED
VISIBLE BLOOD	ABSENT	ABSENT
POLYMORPHONUCLEAR LEUKOCYTES	0 - 1	0 - 5
METHOD: MICROSCOPIC EXAMINATION		
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

MACROPHAGES NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

CHARCOT-LEYDEN CRYSTALS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION
TROPHOZOITES
NOT DETECTED
NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

CYSTS NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

OVA NOT DETECTED

METHOD : MICROSCOPIC EXAMINATION

LARVAE NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

ADULT PARASITE NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

OCCULT BLOOD NOT DETECTED NOT DETECTED

METHOD: MODIFIED GUAIAC METHOD





/HPF

/HPF





**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHT

NEW DELHI 110030 DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

**Test Report Status** Results Units Biological Reference Interval <u>Final</u>

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP 0

METHOD: HAEMAGGLUTINATION (AUTOMATED)

RH TYPE POSITIVE

METHOD: HAEMAGGLUTINATION (AUTOMATED)

XRAY-CHEST

**IMPRESSION** NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO NEGATIVE

**ECG** 

**ECG** T ABNORMALITY IN ANTEROLATERAL LEADS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY CVS 2ND DOSE. RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY ALCOHOL AND SMOKING - OCC.

RELEVANT FAMILY HISTORY HYPERTENSION. DIABETES.

HISTORY OF MEDICATIONS NOT SIGNIFICANT

**ANTHROPOMETRIC DATA & BMI** 

HEIGHT IN METERS 1.78 mts WEIGHT IN KGS. 74 Kgs

BMI 23 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

**GENERAL EXAMINATION** 

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE NORMAL GENERAL APPEARANCE / NUTRITIONAL STATUS HEALTHY BUILT / SKELETAL FRAMEWORK **AVERAGE** FACIAL APPEARANCE NORMAL SKIN NORMAL UPPER LIMB NORMAL LOWER LIMB NORMAL NORMAL NECK

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER



Page 7 Of 13 Scan to View Report





**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

0065VJ002376 AGE: 32 Years SEX: Male ACCESSION NO: ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Units Test Report Status **Biological Reference Interval** <u>Final</u>

THYROID GLAND NOT FNI ARGED

CAROTID PULSATION NORMAL **TEMPERATURE** NORMAL

**PULSE** 80/MIN, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

**BRUIT** 

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

117/82 MM HG ΒP mm/Hg

(SUPINE)

PERICARDIUM NORMAL APEX BEAT NORMAL

HEART SOUNDS S1, S2 HEARD NORMALLY

MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL MOVEMENTS OF CHEST SYMMETRICAL BREATH SOUNDS INTENSITY NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE ABSENT LIVER NOT PALPABLE SPLEEN NOT PALPABLE

ABSENT **HFRNIA** 

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL **JOINTS** NORMAL



Page 8 Of 13 Scan to View Report





CLIENT CODE: C000138379
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

MAHARASHIKA, INDIA Tel: 09152729959/9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: JINU T JOHN PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BASIC EYE EXAMINATION

CONJUNCTIVA NORMAL
EYELIDS NORMAL
EYE MOVEMENTS NORMAL
CORNEA NORMAL

DISTANT VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (6/6)
DISTANT VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (6/6)
NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N/6)
NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT (N/6)

COLOUR VISION NORMAL (17/17)

**BASIC ENT EXAMINATION** 

EXTERNAL EAR CANAL NO ABNORMALITY DETECTED

TYMPANIC MEMBRANE

NO HISTORY OF TYMPANIC MEMBRANE PERFORATION

NOSE

NO HISTORY OF NASAL DISEASE

SINUSES

NO HISTORY OF SINUSITIS

THROAT

NO HISTORY OF THROAT INFECTION

TONSILS

NO HISTORY OF TONSILS

SUMMARY

RELEVANT HISTORY CVS 2ND DOSE.
RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS RAISED FAS'

RAISED FASTING BLOOD SUGAR(102). URINE SPECIFIC GRAVITY LOW (1.000). RAISED DIRECT BILIRUBIN(0.28). RAISED NON HDL CHOLESTEROL(152). RAISED LDL CHOLESTEROL(138). RAISED ALBUMIN(5.0).

RAISED ALBUMIN(5.0). RAISED URIC ACID(7.2)

RELEVANT NON PATHOLOGY DIAGNOSTICS

ECG: T ABNORMALITY IN ANTEROLATERAL LEADS
REGULAR PHYSICAL EXERCISES / LOW CALORIC DIET

REDUCE FATTY AND PROCESSED FOOD IN DIET

REDUCE SUGARS, SWEETS IN DIET INCREASE ORAL FLUID IN DIET.

Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-

REMARKS / RECOMMENDATIONS









**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHT

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

0065VJ002376 AGE: 32 Years SEX: Male ABHA NO: ACCESSION NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Units **Test Report Status Biological Reference Interval** <u>Final</u>

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope. ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays' fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION** 

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

#### LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

#### Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs- insulin,

ethanol, propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents

#### NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose, level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
- 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

HbA1c Estimation can get affected due to:

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.





Page 10 Of 13





**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHT

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

0065VJ002376 AGE: 32 Years SEX: Male ABHA NO: ACCESSION NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Units **Test Report Status Biological Reference Interval** <u>Final</u>

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin entre than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin entre than unconjugated (indi there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis.obstruction of bile ducts.cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilson's disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas.It is also found in other tissues including intestine,spleen,heart, brain and seminal vesicles.The highest concentration is in the kidney,but the liver is considered the source of normal enzyme activity.Serum GGT has been widely used as an index of liver dysfunction.Elevated serum GGT activity can be found in diseases of the liver,billiary system and pancreas.Conditions that increase serum GGT are obstructive liver disease,high alcohol consumption and use of enzyme-inducing drugs etc.Serum total protein,also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

- CREATININE, SERUM-Higher than normal level may be due to:

  Blockage in the urinary tract

  Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- · Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy URIC ACID, SERUM-

Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake.OCP.Multiple Sclerosis

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.



Page 11 Of 13 Scan to View Report





**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

**NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

PLOT No. 88, ROAD No. 15,MIDC ESTATE,ANDHERI (EAST) MUMBAI, 400093

MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

**Test Report Status** Results Biological Reference Interval Units <u>Final</u>

The test is performed by both forward as well as reverse grouping methods.

HISTORY-\* THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL

EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.



Scan to View Report





**CLIENT CODE:** C000138379 **CLIENT'S NAME AND ADDRESS:** 

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHT

NEW DELHI 110030 DELHI INDIA 8800465156

PLOT No. 88, ROAD No. 15, MIDC ESTATE, ANDHERI (EAST)

MUMBAI, 400093 MAHARASHTRA, INDIA

Tel: 09152729959/9111591115, Fax: CIN - U74899PB1995PLC045956

**PATIENT NAME: JINU T JOHN** PATIENT ID: JINUM2803902

ACCESSION NO: 0065VJ002376 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: RECEIVED: 22/10/2022 08:53 REPORTED: 27/10/2022 14:58

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Units Test Report Status <u>Final</u>

### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN

ULTRASOUND ARDOMEN

NO ABNORMALITIES DETECTED

\*\*End Of Report\*\* Please visit www.srlworld.com for related Test Information for this accession

Dr.Rajesh Nayak Consultant Radiologist

### **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062





Scan to View Report